News | December 02, 2021
Molnupiravir, a step closer to approval in the fight against Covid-19
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
Early-stage research suggests the potential to prevent and treat all dengue serotypes and builds on Johnson & Johnson's work to advance science against emerging and entrenched global public health threats
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
The deal is expected to close in the fourth quarter of 2021 and will enable Roche to further expand the portfolio. TIB Molbiol excels in ultra-rapid assay development of emerging infectious diseases
The institute will provide the world’s first unique and comprehensive capability to predict, prevent, respond and to recover from future pandemics
The company to receive upfront and milestone payments, in addition to royalties
Subscribe To Our Newsletter & Stay Updated
